Detalhe da pesquisa
1.
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
Gynecol Oncol
; 129(1): 86-91, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23321064
2.
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Int J Gynecol Cancer
; 18(3): 460-4, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-17854432